Sun Pharmaceutical Industries has informed that the U.S. Food and Drug Administration (USFDA) has granted approval for the New Drug Application (NDA), to a wholly owned subsidiary of the company, for ElepsiaTM XR 1000 mg (levetiracetam 1000 mg) and ElepsiaTM XR 1500 mg (levetiracetam 1500 mg). This product was filed from the company’s Halol (Gujarat, India) facility. The company’s wholly owned subsidiary had in-licensed ELEPSIATM XR from Sun Pharma Advanced Research Company (SPARC) in July 2016.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.95 |
| Dr. Reddys Lab | 1242.75 |
| Cipla | 1230.00 |
| Zydus Lifesciences | 935.00 |
| Lupin | 2337.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: